WuXi AppTec
药明康德
elsewhere's corpus doesn't profile WuXi AppTec directly — it shows up as a supporting player in other companies' stories, and the picture that emerges is of China's dominant pharma R&D services company whose infrastructure the rest of the industry builds on. Per a 蓝驰创投 piece from November 2024, it was then co-producing a key ingredient of Eli Lilly's tirzepatide — with Lilly saying finding an alternative supplier would be "infeasible or take a very long time" — and its oligonucleotide and peptide revenue hit 3.41 billion yuan in 2023, up 64.4% year-on-year with orders on hand up 226% . Its name recurs across the AI-drug-discovery wave: back in 2018, Insilico Medicine used AI algorithms to find a DDR1 small-molecule lead in just 46 days working with WuXi AppTec, as 启明创投 recounts , and TandemAI's Ning Xia landed his earliest commercial collaboration there after demoing his platform to a room full of its executives, per 峰瑞资本 . It also functions as a talent feeder for the ecosystem — figures like Zhigang Chen, its first chief digital officer before founding HeTan AI , and FreeS Fund's Yikai Wang, who worked in its domestic new-drug R&D services division , passed through on their way elsewhere. For a fuller profile — founding, scale, business lines — the corpus here is thin.
AI-generated — may contain errors, please verify.
Coverage
AI for Pharmaceutical Chemical Synthesis: Can Today's AI Match a Chemist with 10 Years of Experience?
AI for Science is becoming one of the hottest directions in the primary market.
Silicon Valley's Booming Longevity Economy, Its Commercial Path Is Right in Front of Us
"The first people who will live to 1,000 may already be alive today."
The "OpenAI Moment" for Pharma Labs: HeTan AI Raises 50 Million Yuan, Robot Scientists Step Onto the Lab Bench
The story of robot scientists has only just begun.
HETAN Intelligence Closes 50 Million Yuan Funding Round, as Robots Make Real Inroads into Labs
Veteran founders with backgrounds at Alibaba, Tencent, and WuXi AppTec.
Qiming Venture Partners' Kan Chen: Investing in Insilico Medicine four years before OpenAI went mainstream, AIDD platform has broad prospects
After completing its investment in Insilico Medicine, Qiming Venture Partners provided the company with sustained support and substantial assistance.
Entrepreneurship Is the Most Hardcore Way for Young People to Change the World | Mono X Campus
Be a long-term partner to founders, not a short-term "referee."
Deep Dive: China's "DeepSeek Moment" in Biotech | FreeS Fund Report
A Watershed Year for China's Innovative Drug Industry
Ban one TikTok, and a thousand TikToks will rise in its place | Undercurrent Worldview
The Perils of Globalization for Chinese Companies
A New Drug King Is About to Be Crowned. Does Peptide Still Have Its Next Billion-Dollar Target? | BlueRun Ventures Viewpoint
You can only find things when you're not looking for them.
Yunqi Capital Attent!on Podcast | Founders Up and Down the Supply Chain: From Embodiment to Intelligence, How Is AI "Awakening" Robots?
Let's Talk About the Messy Reality of Deployment and Application Bottlenecks
Embodied Intelligence + Drug Discovery = ? C12.ai Unveils Industry's First Pharmaceutical R&D Intelligent Robot | Yunqi Capital
Accelerating Drug Discovery and Development
Vol.05 Has AI "Woken Up" the Robots? A Look at the Many Applications and Bottlenecks of Embodied Intelligence
One Step Ahead: Unlocking the N Possibilities of Embodied Intelligence | Yunqi Gathering · Yunqi Capital Demo Day Now Open for Registration
When Embodied Intelligence Comes Knocking
$1 Billion! BioMap and Sanofi Partner to Develop AI Drug Discovery Models Based on Large Foundation Models | BlueRun Ventures Headlines
The First Commercial Partnership Based on Large Language Models in the Life Sciences Sector
What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
Yinjia Biotech Closes Pre-A Round, Advancing Its High-End Protein Platform to New Heights
Build a leading domestic "protein artisan" platform.
Are Returnee Entrepreneurs Losing Their Edge? | 2021 FreeS Fund China-US Venture Forum Transcript
Launch a Startup or Take the "Soft Landing" Through Employment?
Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
In Our Sixth Year, FreeS Fund Is Hiring Investors | Let's Do What's Right, Not What's Easy
Betting on the power of innovation, staying research-driven.
Investment Opportunities in the Pharmaceutical and Chemical Industry Upgrade | Frees Fund
Technology Transfer and Innovation-Driven Growth
2018 was a tough year, but absolutely one with inflection-point significance.
You don't need to get clever or cut corners. Just do what aligns with the cycle and the structure, and you'll make money in this cycle.
Li Feng Column | The Trade War Gets a Comma, but China's Secret Weapon Is Just About to Show Its Edge
What makes China's economic experience distinctive is that much of it consists of "the unintended consequences of human action."
